UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2552) 2552
Newsletter (234) 234
Newspaper Article (211) 211
Magazine Article (52) 52
Book Chapter (7) 7
Trade Publication Article (5) 5
Conference Proceeding (3) 3
Book Review (2) 2
Paper (2) 2
Dissertation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1823) 1823
multiple sclerosis (1755) 1755
science & technology (1548) 1548
life sciences & biomedicine (1473) 1473
interferon-beta - therapeutic use (1026) 1026
interferon beta-1b (1022) 1022
interferon (1015) 1015
female (930) 930
adult (886) 886
neurosciences & neurology (873) 873
male (863) 863
clinical neurology (803) 803
multiple sclerosis - drug therapy (759) 759
interferon beta-1a (749) 749
interferon beta (617) 617
middle aged (599) 599
neurosciences (549) 549
biological response modifiers (469) 469
multiple sclerosis, relapsing-remitting - drug therapy (450) 450
adjuvants, immunologic - therapeutic use (437) 437
treatment outcome (409) 409
neurology (370) 370
research (370) 370
care and treatment (346) 346
drug therapy (337) 337
magnetic resonance imaging (325) 325
interferon-beta - administration & dosage (315) 315
glatiramer acetate (311) 311
interferon-beta - adverse effects (303) 303
abridged index medicus (269) 269
multiple sclerosis - immunology (258) 258
disease progression (249) 249
immunology (223) 223
patients (220) 220
immunologic factors - therapeutic use (212) 212
medicine & public health (200) 200
clinical trials (199) 199
multiple sclerosis - therapy (198) 198
adolescent (197) 197
interferon-beta - immunology (197) 197
peptides - therapeutic use (195) 195
time factors (189) 189
recurrence (184) 184
pharmacology & pharmacy (177) 177
interferon-beta (176) 176
adjuvants, immunologic - administration & dosage (171) 171
follow-up studies (171) 171
immunosuppressive agents - therapeutic use (171) 171
medical research (170) 170
health aspects (169) 169
disability evaluation (168) 168
interferon-beta - pharmacology (164) 164
general & internal medicine (153) 153
medicine, general & internal (153) 153
psychiatry (152) 152
adjuvants, immunologic - adverse effects (151) 151
young adult (151) 151
animals (149) 149
studies (148) 148
pharmaceutical industry (142) 142
medicine (139) 139
dosage and administration (138) 138
medicine, experimental (136) 136
analysis (134) 134
clinical trials as topic (132) 132
research article (131) 131
recombinant proteins - therapeutic use (130) 130
multiple sclerosis - diagnosis (129) 129
aged (127) 127
multiple sclerosis - pathology (123) 123
drug administration schedule (119) 119
prospective studies (119) 119
retrospective studies (118) 118
multiple sclerosis, relapsing-remitting - immunology (117) 117
brain - pathology (116) 116
development and progression (115) 115
dose-response relationship, drug (115) 115
drugs (107) 107
injections, subcutaneous (107) 107
risk factors (106) 106
viral antigens (106) 106
multiple sclerosis - physiopathology (102) 102
cytokines (100) 100
double-blind method (97) 97
neuroradiology (96) 96
biochemistry & molecular biology (95) 95
quality of life (94) 94
multiple sclerosis - blood (91) 91
antibodies (88) 88
recombinant proteins (88) 88
cohort studies (87) 87
multiple sclerosis, chronic progressive - drug therapy (87) 87
nuclear magnetic resonance--nmr (87) 87
usage (87) 87
natalizumab (86) 86
autoimmune diseases (84) 84
randomized controlled trials as topic (80) 80
drug therapy, combination (78) 78
complications and side effects (76) 76
review (76) 76
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2929) 2929
German (51) 51
Russian (36) 36
Spanish (31) 31
French (20) 20
Portuguese (15) 15
Japanese (11) 11
Polish (10) 10
Hungarian (4) 4
Croatian (3) 3
Dutch (3) 3
Italian (2) 2
Persian (2) 2
Turkish (2) 2
Chinese (1) 1
Czech (1) 1
Danish (1) 1
Korean (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 05/2020, Volume 395, Issue 10238, pp. 1695 - 1704
Journal Article
The Lancet (British edition), ISSN 0140-6736, 05/2020, Volume 395, Issue 10238, pp. 1670 - 1671
....8 In The Lancet, Ivan Fan-Ngai Hung and colleagues9 present the results of an open-label, randomised, phase 2 trial that examined the effect of a triple combination regimen of interferon beta-1b 8... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Ritonavir | Severe acute respiratory syndrome | Mortality | Lopinavir | Coronaviruses | Middle East respiratory syndrome | Patients | Ribavirin | Subgroups | Severe acute respiratory syndrome coronavirus 2 | COVID-19 | α-Interferon | Randomization | Respiratory diseases | Interferon | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Multiple sclerosis, ISSN 1477-0970, 07/2016, Volume 4, Issue 2, pp. 70 - 73
Journal Article
Journal Article
Journal of neurology, ISSN 1432-1459, 10/2017, Volume 264, Issue 12, pp. 2436 - 2449
Cognitive impairment (CI) affects 40–65% of multiple sclerosis (MS) patients. This study attempted evaluating the effects of fingolimod and interferon beta-1b (IFN β-1b... 
Neurology | Neurosciences | Interferon beta-1b | Medicine & Public Health | Fingolimod | Brief repeatable battery test | Brain atrophy | Delis–Kaplan executive function test | Neuroradiology | Cognitive impairment | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Cognition Disorders - diagnostic imaging | Humans | Middle Aged | Male | Depression - etiology | Young Adult | Depression - drug therapy | Cognition Disorders - etiology | Statistics, Nonparametric | Electrocardiography | Adult | Female | Fingolimod Hydrochloride - therapeutic use | Multiple Sclerosis, Relapsing-Remitting - complications | Disability Evaluation | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Treatment Outcome | Cognition Disorders - drug therapy | Neuropsychological Tests | Magnetic Resonance Imaging | Pilot Projects | Interferon beta-1b - therapeutic use | Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging | Adolescent | Longitudinal Studies | Executive Function - drug effects | Immunologic Factors - therapeutic use | Complications and side effects | Usage | Multiple sclerosis | Care and treatment | Magnetic resonance imaging | Patient outcomes | Dosage and administration | Neuroimaging | Executive function | Nuclear magnetic resonance--NMR | Cognitive ability | Gadolinium | Interferon | Clinical outcomes | Index Medicus | Original Communication
Journal Article
International journal of pharmaceutics: X, ISSN 2590-1567, 12/2020, Volume 2, pp. 100051 - 100051
The first objective was to investigate the transdermal iontophoresis of interferon beta 1b (IFN); the second was to determine whether the addition of 10 Arg... 
Electromigration | Transdermal iontophoresis | Electroosmosis | Protein delivery | Albumin | Interferon (IFN) | Protein interaction | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology
Journal Article
International journal of pharmaceutics, ISSN 0378-5173, 11/2020, Volume 589, pp. 119913 - 119913
[Display omitted] The first objective was to investigate the transdermal iontophoresis of interferon beta 1b (IFN); the second was to determine whether the... 
Electromigration | Transdermal iontophoresis | Electroosmosis | Protein delivery | Albumin | Interferon (IFN) | Protein interaction | Index Medicus
Journal Article